GlassScriptPhysician profile
Carreen Castroll
NPI 1639313398
$14,941.92
in general payments reported to CMS, 2019-2025
29 companies · $2,366 in 2025
The $2,366 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,285 · 2022: $2,584 · 2023: $3,092 · 2024: $2,614 · 2025: $2,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,072.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,692.18 | 2021-2025 | |
| Alkermes, INC. | $1,575.52 | 2021-2025 | Aristada, Lybalvi |
| Validus Pharmaceuticals LLC | $1,347.79 | 2021-2023 | Equetro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,271.19 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,176.23 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,034.26 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $1,007.01 | 2021-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $899.53 | 2023-2025 | Sunosi, Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $806.61 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $771.58 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $601.64 | 2021-2025 | Rexulti, Abilify Maintena |
| Bausch Health US, LLC | $348.51 | 2021-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $337.83 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $331.13 | 2021-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $302.25 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $278.36 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $201.50 | 2024-2025 | Cobenfy |
| Alfasigma USA, INC. | $182.74 | 2021 | |
| Jazz Pharmaceuticals INC. | $135.31 | 2021-2022 | |
| Indivior INC. | $121.36 | 2021-2022 | |
| Eisai INC. | $100.46 | 2021-2022 | |
| Tris Pharma INC | $98.94 | 2023-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $84.08 | 2021 | |
| Novo Nordisk INC | $65.03 | 2021 | |
| Corium, LLC | $58.71 | 2024-2025 | Azstarys |
| Orexo US, INC. | $40.57 | 2024-2025 | Zubsolv |
| Livanova USA, INC. | $27.75 | 2021 | |
| Supernus Pharmaceuticals, INC. | $23.41 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.44 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carreen Castroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.